Skip to main content

Follow our Journeys

Sharing success stories internal to Duke Capital Partners and external to our portfolio companies.

Tune Therapeutics Completes Over $175M in Series B Financing to Advance Field-Leading Epigenome Editing Programs

13th Jan 2025

Tune Therapeutics, a Duke Capital Partners portfolio company, is a Duke spinout cofounded by Professor Charles Gersbach (BME, Pratt).

Read More

Durham-based Acre Homes Raises Over $10MM from VCs Amid Growing Consumer Demand for Single Family Housing Solutions

DANNCE.AI Raises $2.6 Million; Launches to Provide Clinicians and Drug Developers an AI Biomarkers Platform to Characterize Drug Effects and Optimize Neurological Care

Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B

Faisal Anees headshot

Associate Spotlight: Faisal Anees

Orange Carpe logo on a white background.

Sweaty Palms Move From Dorm Room to Board Room

A stylized illustration depicts a lab and office setting. The scene is illuminated by artificial blue light from within the lab and office and a warm glow from an opening door in the middle. In the foreground, a feminine figure with medium hair in a ponytail, wearing a lab coat and carrying a briefcase, is walking towards the right, silhouetted against a brightly lit doorway. On the left are a few figures in a lab setting, with one seated at a desk with a computer screen. Inside the office on right, there are three figures in professional attire seated around tables with a laptop on it.

From Interns to Employees: Duke Trainees Find Full-Time Home at OTC